Carb-X

Institut Pasteur Financing Start-Up Breakfast
2019-09-10
Additional Details Forthcoming.

Live Webinar: GARDP/REVIVE – Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research
2019-09-10 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
In this webinar, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial research.
This webinar is designed as a follow on from the webinar of William J. Weiss: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research (see here: http://bit.ly/2ZiPt6y).
Topics covered in this webinar will include:

In depth review of animal models of pneumonia, UTI and tissue infections including biofilm models.
Animal models of non-traditional drugs where CFU might not be a suitable biomarker.
Tips, hints and pitfalls when trying to generate informative data in PKPD studies.

The presentation will be followed by a Q&A session.

Speaker:
Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec
Moderator:
William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy
Register here for this live webinar.

AMR Challenge: A Night Celebrating Global AMR Fighters
2019-09-23 18:00 - 21:00 (America/New_York) | Cipriani Midtown, 110 E. 42nd Street, New York City, NY, 10017, United States
Join HHS Secretary, Alex Azar, experts from the U.S. Centers for Disease Control and Prevention, and hundreds of organizational and global leaders for an evening celebrating the culmination of the AMR Challenge at an unofficial side event of the 74th United Nations General Assembly in New York City.

IDWeek 2019 Annual Conference
2019-10-02 - 2019-10-06 | Walter E. Washington Convention Center, 801 Mount Vernon Pl. NW,, Washington D.C., DC, 20001, United States
Attendees include Richard Alm, CARB-X Alliance Director.
IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).
At IDWeek, you will see familiar colleagues and new faces. IDWeek is a forum for health professionals of varied backgrounds to collaborate, cooperate, and learn from each other’s expertise. With so many common issues and challenges cutting across our four disciplines, IDWeek provides an opportunity to learn from each other’s knowledge, experience and expertise, for the improvement of patient care and public health.
This is an inclusive meeting that offers access to internationally recognized leaders in the field and the opportunity to network with the most highly respected health professionals in infectious diseases, including HIV.
To learn more, click here.
To view the program, click here.
To register for the conference, click here.

Live Webinar: GARDP/REVIVE – Natural products antibiotics: from traditional screening to novel discovery approaches
2019-10-03 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
In this webinar, Olga Genilloud will discuss the role of natural products in current antibiotic discovery. Topics discussed will include:

Screening strategies to identify novel antibiotics
Current challenges and novel analytical tools
New omic approaches supporting antibiotic discovery

The presentation will be followed by a Q&A session.

Speaker:
Olga Genilloud, Scientific Director, Fundación MEDINA, Granada, Spain
Moderator:
Laura Piddock, Director of Scientific Affairs, GARDP
Register here for this live webinar.

Live Webcast: Drug-Resistant Infections: Confronting an Escalating Crisis
2019-10-11 12:00 - 13:00 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Antibiotics are a pillar of modern medicine. They have saved millions of lives and added some 20 years to human life expectancy. But as the use of antibiotics has increased, so has the proliferation of antibiotic-resistant microbes that have adapted to survive most, or all, of today’s antibiotics. The CDC reports that two million people are infected with drug-resistant bacteria every year in the United States, and the Review on Antimicrobial Resistance estimated that, around the world, 700,000 people die of such infections annually. That number stands to increase: the Review predicts that, by 2050, drug resistance could be responsible for 10 million deaths a year. And while these numbers are dominated by bacterial infections, fungal infections like Candida auris are also a threat, especially to vulnerable patients in hospitals and nursing homes.
Despite drug resistance growing, the development of new antibiotics has slowed. How can policymakers help accelerate the pace of new drug development. How can all of us—doctors, hospitals, and patients, as well as the agricultural sector—be better stewards of existing drugs? Forum panelists will examine the scope of this looming crisis and look at how changes in policy and practice can help us stay one step ahead of these superbugs.
Moderator
David Freeman, Editorial Director of NBC News MACH
Panelists
Helen Boucher, Director, Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR) and Professor of Medicine at Tufts University School of Medicine
Lauri Hicks, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention
Marc Lipsitch, Professor of Epidemiology and Director of the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health
Kevin Outterson, Executive Director of CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), and Professor of Law, Boston University
Part of: The Dr. Lawrence H. and Roberta Cohn Forums.
Presented jointly with NBC News Digital
Live webcast will be on Friday, October 11, 2019, 12:00pm – 1:00pm ET.
An on-demand video will be posted after the event.
To learn more, click here.

Institut Pasteur - International Course on Antibiotics and Resistance (ICARE)
2019-10-19 - 2019-10-27 | Les Pensieres, Annecy, France
Speakers include Erin Duffy, CARB-X Chief of Research and Development.
The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is currently no course providing advanced instruction on antibiotics and resistance. The specific goal of ICARe is to bring leaders in academics and industry together with trained scientists at the dawn of their careers. Cutting-edge approaches for detection of resistance and antibiotic discovery, chemical optimization, and usage that minimizes the development of resistance will be examined.
The objective of the course is to train the next generation of scientists implicated in the study of bacterial resistance to antibiotics and the finding of new drugs. The faculty is composed of 40 internationally recognized scientists and physicians who have made important contributions to antibiotic development, and infectious diseases and resistance management. Faculty will be in residence for a minimum of two days and accessible for informal interactions. Graduates will emerge with a state-of-the-art understanding of existing antibiotics: modes of action, pharmacology, toxicology, mechanisms of resistance, impact of antibiotics on human and other ecologies, current approaches for mining chemical space for antimicrobial activity, the process of advancing hits to leads, the application of next generation nucleic acid-based technologies for antibiotic discovery and resistance detection, and perhaps, most importantly, training and experience in thinking creatively and innovatively about solutions to the problem. The course aims to build an international cadre of collaborative, well networked, and highly trained specialists.
To learn more, click here.
To register for the course, please click here.
Please note that registration is currently open and will close on May 17th.

Challenges in Antimicrobial Resistance - A Conversation with Kevin Outterson
2019-11-04 16:00 - 18:00 (America/New_York) | Harvard Chan School of Public Health, 677 Huntington Ave FXB 301, Boston, MA, 02115, United States
Kevin Outterson, Executive Director of CARB-X, will be speaking at the Harvard Chan School of Public Health.
This presentation is sponsored by Harvard Antimicrobial Resistance (HAMR) a subgroup of the Harvard Infectious Diseases Consortium.

For more information, visit harvardamr.com

World Anti-Microbial Resistance Congress 2019
2019-11-07 - 2019-11-08 | Renaissance Washington DC Downtown Hotel, 999 9th St NW, Washington, DC, 20001, United States
Kevin Outterson, Executive Director of CARB-X, will be giving the keynote Address on November 7th, titled “A vision for a health antibiotic R&D ecosystem”. Outterson will also be participating on a panel titled “Analyzing the potential impact of current commercial and “pull” initiatives” on November 7th.
Karen Gallant, Deputy Executive Director of CARB-X, will be presenting on November 7th on “Accelerating innovation to fight drug-resistant bacteria”.
About the World AMR Congress:
Since 2015, the World Anti-Microbial Resistance Congress has been the only commercially focused conference globally of its kind. Launched during the release of key reports such as the AMR Review and A Scientific Roadmap for Antibiotic Discovery, the World AMR Congress has brought attention to the threats of this emerging crisis to the global healthcare system. The conference gathers global leaders in infectious diseases to meet, brainstorm and discuss the challenges and opportunities on seven topic areas:

Antibiotic R&D: advancing the development of antibiotic and non-traditional therapies and improving commercialization strategies
Diagnostics: innovating the development and deployment of rapid diagnostics tests, while ensuring an effective integration into hospitals’ workflow and reimbursement
Antimicrobial stewardship: using technology to improve antibiotic prescription, monitoring and surveillance while advancing stewardship-based purchasing guidelines
Pitch & Partner: joining funding and partnerships with antibiotics and diagnostics innovation
Infection Control: advancing policies to improve infection prevention, control and compliance in healthcare facilities
Manufacturing: overcoming challenges for a sustainable and controlled antibiotic manufacturing and supply chain
Vaccines: discussing the clinical and economic value of vaccines to combat AMR

To learn more, click here.
TO view the agenda, click here.
To register, click here.

Live Webinar: GARDP/REVIVE – Converting Gram-positive-only compounds into broad-spectrum antibiotics
2019-11-07 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois, US) will detail his research group’s efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis will be placed on the practicality, actionability, and translatability of this information, specifically, the use of accumulation rules to convert high-value Gram-positive-only compounds into antibiotics with activity against key Gram-negative pathogens.
The presentation will be followed by a Q&A session.
Speaker:
Paul Hergenrother, Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry, University of Illinois
Moderator:
Laura Piddock, Director of Scientific Affairs, GARDP
Register here for this live webinar.

CRISPR and Gene Editing: The New Frontier in Fighting Infectious Diseases?
2019-11-12 16:00 - 19:00 (America/Toronto) | JLabs @ Toronto, 661 University Ave Suite 1300, Toronto, Ontario, Canada
Presenters include Karen Gallant, Deputy Executive Director of CARB-X.
Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on the world.
With scientific promise comes interest from investors – a surge of biotech startups are utilizing CRISPR technology for many different applications such as at-home testing, in-clinic uses, and more. “This incredibly powerful repurposing of the bacterial immune system has created an outpouring of financial backing for small companies with revolutionary technological advancement in genome engineering-based ventures.”[1]
On November 12th, we will explore this subject with presentations from experts in the field, startup companies innovating in this space, and investors looking to invest in these new applications.
To learn more, click here.

The 2019 Canada Gairdner Foundation / Ontario International Symposium: Fuelling the Fight against AMR - Global Innovations in Research & Discovery
2019-11-14 - 2019-11-15 | McMaster University, 1280 Main Street W, Hamilton, Ontario, L8S 4L8, Canada
Kevin Outterson, Executive Director of CARB-X, is participating in a special panel discussion titled “When antibiotics fail: An international conversation about the worrisome evidence of impact and what can be done”. During this session, a panel of international experts will discuss the findings from a new report by the Council of Canadian Academies and discuss what steps can be taken to reduce the impact of rising resistance rates around the world. Additional panelists include Prof. Andrew Morris, Prof. Dame Sally Davies, and Prof. Kathryn Holt.
About the Symposium:
Each year, the Gairdner Foundation invites Universities, Organizations and Research Institutes across Ontario to submit proposals to host a partnered international symposium on the frontiers of biomedicine.
This year, the Michael G. DeGroote Institute for Infectious Disease Research and David Braley Centre for Antibiotic Discovery at McMaster University were honored to have been selected to host the 2019 Gairdner event on the growing global crisis of antimicrobial resistance (AMR).
Drawing on the Canada Gairdner Awards’ history of recognizing the best in biomedical science, this symposia will bring leading experts from across the world to present on the state of the international AMR challenge and to showcase recent global advances in AMR research and discovery.
To learn more, click here.
To register, click here.

FDA Workshop: Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States
2019-11-18 - 2019-11-19 | FDA White Oak Campus – Building 31, 10903 New Hampshire Ave, Silver Spring, MD, 20993, United States
Presenters include Kevin Outterson, Executive Director of CARB-X, and Erin Duffy, CARB-X Chief of Research and Development.
The FDA, IDSA, NIAID and Pew are co-sponsoring this workshop to focus on Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States. This workshop will bring together a diverse array of subject matter experts in the fields of infectious diseases (ID), academics and industry and other government bodies to better understand the current state of U.S. based ID trials and how to enhance enrollment and research in such trials.
To learn more, click here.
Registration:
Those who are interested in attending this public workshop either in-person or by web viewing must register here by 11:59 pm on November 14, 2019. Onsite registration will begin at 7:30 am the day of the meeting. Please plan to arrive 30 minutes prior for security processing.

Live Webinar: GARDP/REVIVE – Innovation in point-of-care diagnostics for sepsis and bloodstream infections
2019-11-26 03:30 - 05:00 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
In this webinar our moderator Caroline Purslow (Nesta Challenges) will welcome three speakers.
Till Bachmann (University of Edinburgh) will give an overview of recent advances in AMR diagnostics development. He will discuss:

State of the art approaches for diagnosing infections and AMR
Pipeline of promising tests
Challenges of adoption

Amrita Sukrity (SpotSense) will draw from her experience as a founder of SpotSense and talk about diagnosis of neonatal sepsis at the community level. Topics discussed will include:

Challenges across diagnosing newborn sepsis in NICU vs. in the community
Identifying different phases of sepsis by combining risk parameters and biomarker data
Creating outlines for biomarker-based differential diagnosis: work ahead

And finally, David Anderson’s (Burnet Institute) presentation ‘CD64 as a host-response biomarker in sepsis and severe infections’ will cover:

Limitations of flow cytometry for CD64 as a diagnostic tool of sepsis and severe infections in emergency situations
Novel observations on CD64 biology that should facilitate more sensitive a point-of-care (POC) diagnostic tests for sepsis and severe infections
The ongoing development of a POC diagnostic test for neutrophil CD64

The presentations will be followed by a Q&A session.
Register here for this live webinar.
A recording of this webinar will be available on revive.gardp.org/webinars.

Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives
2020-01-16 10:30 - 16:30 (America/New_York) | Washington Marriott at Metro Center, 775 12th Street NW, Washington, DC, 20005, United States
Speakers include Kevin Outterson, Executive Director of CARB-X.
The rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities, in part due to payment decisions that don’t reflect the value of antibiotics that extends beyond the hospital stay. For years, policy makers and other stakeholders have been exploring ways to improve the antibiotic ecosystem through development, regulatory, and market incentives proposals, though to date there has been limited impact on manufacturers’ ability to generate adequate ROI.
This public meeting will highlight recent actions implemented by stakeholders in the U.S. and globally, and present additional opportunities to effect change to payment and the costs and returns to antimicrobial investment systems through legislative, administrative, and private sector mechanisms.

Davos 2020 World Economic Forum - Novo Nordisk Foundation and Novo Holdings: The Broken Model of Antimicrobial resistance
2020-01-21 08:00 - 17:00 (America/New_York) | DAVOS-KLOSTERS, Switzerland
Moderator: Kevin Outterson, Executive Director, CARB-X, Professor of Law, Boston University
Panel:

Lars Rebien Sorensen, Chairman of the Novo Nordisk Foundation and Novo Holdings
Jeremy Farrar, Director, Wellcome Trust
Dr. Malin Grape, Head of Antibiotics Unit, The Public Health Agency of Sweden
Thomas Cueni, Director General, IFPMA
Jayasree K. Iyer, Executive Director, Access to Medicine Foundation
Francesca Colombo, Head of the Health Division, OECD

Antimicrobial resistance is one of the biggest threats to human health. The Novo Nordisk Foundation is hosting a session at the World Economic Forum’s Annual Meeting in Davos urging governments, the biopharma industry and other stakeholders to step up the urgency and respond to the crisis in #antimicrobialresistance with new funding models.
To watch a recording of this panel, please click here.

Live Webinar: GARDP/REVIVE - Testing for the potential of emergence of antimicrobial resistance
2020-01-21 11:00 - 12:30 (America/New_York)
In this webinar, the following aspects will be presented:

What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?
What are some techniques that may be used to understand the origins of resistance selection?
How to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?

The presentation will be followed by a Q&A session.
This presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’, jointly organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019.

Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec (France)
Moderator: Laura Piddock, Director Scientific Affairs, GARDP
Register here for this live webinar.

Live Webinar: GARDP/REVIVE - Non-traditional antibacterial therapeutic options and challenges
2020-02-04 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
In this webinar, the following aspects will be presented:

Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline
These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation
Some of these approaches require novel preclinical efficacy models to predict clinical outcome
Pathogen-specific or even patient-specific strategies dominate this field
A major challenge will be to show efficacy in clinical trials

The presentation will be followed by a Q&A session with Ursula Theuretzbacher and Laura Piddock (GARDP).
Speaker: Ursula Theuretzbacher, CEFAIA, Austria
Moderator: Prabhavathi Fernandes, Chair of GARDP’s Scientific Advisory Committee
Register here for this live webinar.

Live Webinar: GARDP/REVIVE - PK/PD murine infection models: Focus on study elements, variability, and interpretation of results
2020-02-27 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
In this webinar, Alexander J. Lepak will review critical study elements that lead to robust preclinical PK/PD results in the murine model.
Topics discussed will include:

Understanding and embracing the inherent variability in many components of the murine model
Demonstrating how to generate and interpret preclinical murine model PK/PD results

The presentation will be followed by a Q&A session.
The material presented in this webinar was shown but not recorded at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019.
Speaker: Alexander J. Lepak, Assistant Professor, Department of Medicine, University of Wisconsin School of Medicine and Public Health (USA)
Moderator: Peter Warn, Evotec (UK)
Register here for this live webinar.

BAARN2020: Boston Area Antimicrobial Research Network Meeting
2020-03-20 09:00 - 17:00 (America/New_York) | Harvard Campus, 52 Oxford Street, Cambridge, MA, 02138, United States
The Boston Area Antimicrobial Resistance Network Meeting, to be held on Friday, March 20th.

BAARN2020 will be the 7th iteration of this flagship MSI event, bringing together our collective talents across academia and industry to address the persistent dilemma posed by antimicrobial resistant infection.

Talks will begin at 9 AM in the Northwest Labs Building at 52 Oxford Street, Cambridge MA 02138, and our sessions will conclude with the annual Stuart Levy Lecture. A reception will follow at 6 PM at the Harvard Museum of Natural History next door.

Live Webinar: GARDP/REVIVE – Inhaled antimicrobials: Do we get the drug to the bug?
2020-04-28 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Harm A. W. M. Tiddens, Professor of Pediatric Pulmonology and Allergology, Erasmus Medical Center Sophia Children’s Hospital (Netherlands)
Moderator: Harpal Singh Dhillon, Global Medical Value Director & Founder, AntiBx (UK)

In this webinar, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this can impact upon the deposition pattern and efficacy of inhaled antibiotics. He will further present the learnings of his research group’s computational fluid dynamic modelling studies and explain why the expectation that inhaled antibiotics result in high concentrations in the lung is unfortunately a misconception.
The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 28 April, 17:00-18:30 CEST (find your time zone here).

Live Webinar: GARDP/REVIVE – Probability of target attainment analyses for dose selection in antimicrobial drug development
2020-05-12 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)
Moderator: Vincent H. Tam, Professor, University of Houston (US)
In this webinar, Shampa Das will give an overview of her work in studying the PK/PD and probability of target attainment for dose selection.
Topics discussed will include:

An overview of what is meant by the probability of target attainment (PTA)
How it is calculated and what data is used for this
How PTA is used for decision making during drug development

The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 12 May 2020, 17:00-18:30 CEST (find your time zone here).

Live Webinar: GARDP/REVIVE – Assay development for measuring antibiotic accumulation in Gram-negative bacteria
2020-05-19 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers:

Jessica Blair, Institute of Microbiology and Infection, University of Birmingham (UK)
Mark Brönstrup, Department of Chemical Biology, Helmholtz Centre for Infection Research (Germany)
David A. Six, Venatorx Pharmaceuticals, Inc. (US)

Moderator: Alice Erwin, Erwin Consulting LLC (US)
The presentation will be followed by a Q&A session.
Register now for this live webinar.

Live Webinar – CARB-X - How to Prepare for an FDA Pre-IND Meeting: Planning for Success
2020-05-28 12:00 - 13:00 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers:
Carmella Moody, Regulatory Program Director, RTI International
Michael Bevilacqua, M.D., Ph.D., Chief Executive Officer and Chief Science Officer, Amicrobe Inc.
In this webinar, Carmella Moody and Michael Bevilacqua will help product developers understand how best to prepare for pre-IND meetings to ensure maximum results.
Carmella Moody has many years experience supporting and preparing companies for pre-IND meetings. Michael Bevilacqua, who worked with CARB-X to prepare for his company’s recent pre-IND meeting, will discuss his positive experience and lessons learned. Everyone is welcome to join. A recording of the webinar will be available for those who cannot attend the live broadcast.
Presentations will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on May 28, 12:00 to 13:00 ET (find your time zone here).

Live Webinar: o2h ventures 6th ChaiTime Webinar Registration
2020-05-29 10:00 - 11:30 (America/New_York) | Webinar
Join us on Friday, May 29 @ 3:00 PM BST (10:00 AM EST / 7.30 PM IST) for our the sixth o2h ventures ChaiTime webinar on ‘Antibiotic Resistance – The fight for humanity’.
Erin Duffy, Chief of R&D, CARB-X , will chair the 6th o2h ventures ChaiTime discussion on drug resistance and lessons to be learned fron the COVID-19 pandemic.
Click Here to Register for the Webinar.
Webinar Chair:
Erin Duffy, Chief of R&D @ CARB-X
Panelists and Speakers:
Ken Bradley, Global Head, Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED)
Ankit Mahadevia, CEO of NASDAQ listed, Spero Therapeutics
Paul Finn, CEO of Oxford University Spinout, Oxford Drug Design
Ajay Mistry, CEO of AI and antibiotics discovery start-up, Oppilotech

Live Webinar: GARDP/REVIVE – Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations
2020-06-09 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Vincent H. Tam, Professor, University of Houston College of Pharmacy (USA)
Moderator: Shampa Das, Senior Lecturer, Centre of Excellence in Infectious Diseases Research, University of Liverpool (UK)
In this webinar, Vincent H. Tam will present on his work looking at studying PK/PD in fixed dose beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations.
Topics discussed will include:

Understanding the inherent challenges associated with PK/PD of BL/BLI combinations
Demonstrating new approaches to gain useful insights from preclinical PK/PD models

The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 9 June 2020, 17:00-18:30 CEST (find your time zone here).

JLABS Webinar: Pulse Check-Today's Funding Landscape
2020-06-09 12:00 - 13:00 (America/New_York) | Webinar
Today’s current crisis has changed the mindset of many industry strategic partners, investors and overall stakeholders. From pivoting investment priorities, to identifying new areas of innovation, the investor landscape is constantly shifting.
For small to medium sized biotechs, it can be hard to keep up with promised milestones while also planning and anticipating the future of their companies. How could companies be preparing for not only the short-term but for years to come? What should be prioritized in the coming months? Who is still investing? How can they find the right partners for them as they move forward?
Join JLABS as we welcome members of Johnson and Johnson Development Corp., and other industry investors to:

Share how they are planning for the future and pivoting in the current crisis
What they believe companies should be prioritizing
How bio-techs could stay connected with their current and potential stakeholders
Where they could find the right resources and investment opportunities, and overall gain a pulse check on the investor community

To learn more, click here.

JLABS Webinar: Raising Capital: A Legal Primer
2020-06-25 11:00 - 12:15 (America/New_York) | Webinar
Having a clear strategy for raising growth capital and understanding the evolution and dynamic of investment deals are essential for the long-term health of your business. Join JLABS, Allen & Overy and O’Melveny to learn more and discuss key issues such as:

Key points in growth capital deals
Evolution of deal dynamics
Board seats
Governance structure
Economic terms
Exit terms

To learn more, click here.

This program is part of the Johnson & Johnson Innovation – JLABS Legal Webinar Series for life science entrepreneurs, together with Allen & Overy and O’Melveny. You can register for other webinars in the series by visiting this page.

Live Webinar: GARDP/REVIVE – Clinical development of antimicrobials – Phase 1 development challenges
2020-06-30 11:00 - 12:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speaker: Markus Zeitlinger, Head of Department of Clinical Pharmacology, Medical University of Vienna (Austria)
Moderator: Markus Heep
The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 30 June, 17:00-18:30 CEST. Find your time zone here.

Live Webinar: GARDP/REVIVE – The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
2020-07-09 03:00 - 04:30 (America/New_York) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers:

Anand Anandkumar, Co-founder and CEO Bugworks Research Inc (India)
Kamini Walia, Program Officer, ICMR-AMR Initiative (India)

Moderator: François Franceschi, GARDP
In this webinar, Anand Anandkumar and Kamini Walia will discuss:

Why is India one of the hotbeds of the AMR problem? Latest statistics of growing drug resistance etc.
Initiatives of the Indian Government to curb the AMR problem
Antimicrobial R&D landscape in India – a vibrant ecosystem supporting innovation in AMR diagnosis, prevention and therapeutics
Fledgling antimicrobial clinical trial networks – could trials out of India play a significant role in gaining global regulatory approvals?
Changing regulatory environment to enable accelerated approvals for antimicrobial products

The presentation will be followed by a Q&A session.
Register now for this live webinar including interactive Q&A session on 5 May 2020, 9:00-10:30 am CEST (find your time zone here).
